Analytical Data
-
Gene name
SYTL2
- Application
-
Alternative Names
CHR11SYT; SGA72M; SLP2; Exophilin-4; Breast Cancer-Associated Antigen SGA-72M
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9HCH5
-
Expression Region
Lys329~Leu880
-
Molecular Weight
33kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
SYTL2 (Syntaxin-1A- and Syntaxin-3-binding protein 2) belongs to the synaptotagmin-like protein family and plays a vital role in cellular processes, particularly in membrane trafficking and cytoskeletal organization. This protein is primarily expressed in neuronal tissues, suggesting its involvement in synaptic function and neurotransmitter release. Recent studies indicate that SYTL2 may act as a mediator in the transport of vesicles along the actin filaments, crucial for the dynamic processes of synaptic vesicle cycling. Dysregulation of SYTL2 has been associated with various neurological disorders, including neurodegenerative diseases and synaptopathies, highlighting its potential as a therapeutic target. The characterization of SYTL2 as a recombinant protein is pivotal for understanding its structural and functional properties, enabling researchers to investigate its interactions with other cellular components. In vitro studies using SYTL2 recombinantly expressed in suitable systems allow for detailed analysis of its binding affinities and mechanisms of action, which are essential for elucidating its role in neuronal communication and plasticity. As research continues to unveil the intricate network of protein interactions in the nervous system, SYTL2 stands out as a candidate worth exploring further, offering insights into both basic neurobiology and potential intervention strategies for synaptic dysfunction.
